Research programme: anti-infective monoclonal antibodies - Mapp Biopharmaceutical

Drug Profile

Research programme: anti-infective monoclonal antibodies - Mapp Biopharmaceutical

Alternative Names: Anti-Clostridium difficile monoclonal antibodies - Mapp; Antiviral monoclonal antibodies - Mapp; Junin virus anti-infective monoclonal antibodies - Mapp; Marburg virus anti-infective monoclonal antibodies - Mapp; Multi-antibody prevention product - Mapp/IPCP; Respiratory syncytial virus anti-infective monoclonal antibodies - Mapp; Venezuelan equine encephalitis antiviral monoclonal antibodies - Mapp

Latest Information Update: 23 Jan 2015

Price : $50

At a glance

  • Originator Mapp Biopharmaceutical
  • Developer Baylor College of Medicine; Defence Research and Development Canada; Defence Science and Technology Laboratory; Iowa State University; Mapp Biopharmaceutical; Public Health Agency of Canada; The Scripps Research Institute; United States Army Medical Research Institute of Infectious Diseases; University of Texas Medical Branch
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections; Encephalitis virus infections; Junin virus infections; Marburg virus disease; Respiratory syncytial virus infections

Most Recent Events

  • 23 Jan 2015 Preclinical trials in Respiratory syncytial virus infections in USA (Parenteral)
  • 23 Jan 2015 Preclinical trials in Marburg virus disease in USA (Parenteral)
  • 23 Jan 2015 Preclinical trials in Junin virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top